# Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Solid Tumors

> **NCT00024661** · PHASE1 · COMPLETED · sponsor: **INSYS Therapeutics Inc** · enrollment: 30 (—)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** LErafAON

## Key facts

- **NCT ID:** NCT00024661
- **Lead sponsor:** INSYS Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-03
- **Primary completion:** —
- **Final completion:** 2004-10
- **Target enrollment:** 30 (—)
- **Last updated:** 2011-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00024661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00024661, "Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00024661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*